Lercaprel

Enalapril maleate and lercanidipine hydrochloride, the active ingredients in Lercaprel, are an ACE inhibitor and calcium‑channel blocker combination presented as an oral tablet for adult use. The product is indicated for the treatment of hypertension, helping to lower blood pressure in patients requiring dual‑mechanism therapy and is available in the European market.

GNH USA supplies Lercaprel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Lercaprel, a combined ACE inhibitor and calcium‑channel blocker, is used to manage conditions within the hypertension disease family.

- Hypertension: lowers systolic and diastolic blood pressure in adult patients. - Essential hypertension: provides combined ACE inhibition and calcium‑channel blockade for improved control. - High blood pressure: reduces vascular resistance and cardiac workload. - Cardiovascular risk reduction: assists in decreasing the risk of stroke and heart attack associated with elevated blood pressure. - Isolated systolic hypertension: effectively reduces elevated systolic pressure in older adults.

Lercaprel may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Cough: dry or tickling sensation in the throat. - Dizziness: light‑headed feeling, especially after standing. - Headache: mild to moderate intensity. - Flushing: warmth and redness of the face or neck. - Peripheral edema: swelling of ankles or lower legs. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Angioedema: swelling of lips, tongue, or airway requiring emergency care. - Severe hypotension: marked drop in blood pressure causing faintness. - Hyperkalemia: elevated blood potassium levels that may affect heart rhythm. - Acute renal impairment: sudden decrease in kidney function. - Hepatic dysfunction: abnormal liver enzyme elevations. - Neutropenia: low white‑blood‑cell count increasing infection risk.

When prescribing Lercaprel, clinicians should consider several precautionary measures to ensure patient safety.

- Renal function: monitor creatinine and eGFR in patients with existing kidney disease. - Electrolytes: check serum potassium regularly, especially when combined with potassium‑sparing agents. - Pregnancy: avoid use unless clearly necessary, as safety data are limited. - Concomitant ACE inhibitors: do not co‑administer with other ACE inhibitors or ARBs to prevent excessive renin‑angiotensin blockade. - Hypotension: observe patients for symptomatic low blood pressure after the first dose. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Lercaprel can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may cause dangerous hyperkalemia when combined. - Aliskiren in diabetic patients: increases risk of renal impairment and hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: can diminish antihypertensive effect and affect renal function. - Lithium: concurrent use may raise lithium serum concentrations. - Rifampin: may lower plasma levels of both enalapril and lercanidipine, reducing blood‑pressure control.